Call Buyers Blitz Rallying bluebird bio, Inc. (BLUE)

bluebird bio Inc (BLUE) calls stay hot as the biotech assails record heights

by Andrea Kramer

Published on Mar 11, 2015 at 1:22 PM
Updated on Apr 20, 2015 at 5:32 PM

Biotech concern bluebird bio Inc (NASDAQ:BLUE) is continuing its assault on the charts, up 1.4% at $118.75. In fact, the shares earlier notched an all-time best of $122.70. Against this backdrop, BLUE bulls are active in the options arena, with calls trading at twice the average intraday clip.

Most popular is the April 110 call, which traders are buying to open to gamble on an extended journey north of $110 through the next five weeks. The volume-weighted average price (VWAP) of the call is $17.75, meaning the buyers will profit if BLUE topples $127.75 (strike plus VWAP) -- in uncharted territory -- by the close on Friday, April 17, when back-month options expire.

Today's bullish campaign is nothing new for BLUE speculators. Option traders on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have bought to open nearly 1.5 calls for every put during the past two weeks.

On the charts, bluebird bio Inc (NASDAQ:BLUE) has been a monster, more than quadrupling over the past year. More recently, the shares have outperformed the broader S&P 500 Index (SPX) by 35 percentage points during the past month, bringing the stock's 14-day Relative Strength Index (RSI) to 81 -- in overbought territory, suggesting a breather could be in the short-term cards.

Daily Chart of BLUE since March 2014

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.